HGH and the FDA Approval Anti Aging


	FDA Approves HGH By Marc Kaufman Washington Post Staff Writer Saturday, July 26, 2003 FDA Approves Wider Use of Human Growth Hormone The use of human growth hormone to treat children who are healthy but unusually short was approved yesterday by the Food and Drug Administration -- the first time that the agency has embraced use of the controversial drug to treat unexplained shortness. To advocates of the approval, it offers new possibilities for very small children who suffer from a growth disorder. But critics have attacked the expanded use as a misguided effort to turn a cosmetic or social problem into a medical one. Biotech Headlines Researchers Turn To Adult Stem Cells (The Washington Post, Aug 20, 2004) BioVeris Files Delayed Report (The Washington Post, Aug 17, 2004) BearingPoint Wins ID Project at TSA (The Washington Post, Aug 16, 2004) The FDA based its decision on studies that found the biosynthesized hormone Humatrope added between one and three inches in height to children who took it for four to six years, and that there were no significant health risks for the children. The drug has been available since the late 1980s, but it had been approved by the FDA only for shortness caused by specific diseases and syndromes. The new approval is for shortness -- defined as an adult height of less than 5 feet 3 inches for men and 4 feet 11 inches for women -- without a known cause. next page

	key words: HGH, Human growth hormone, anti aging, Hgh Plus

Ingredients